Slim Adcomm Majority Boosts Sarepta’s Gene Therapy In Duchenne Muscular Dystrophy

 
• By Derrick Gingery

Accelerated approval seems imminent after a majority of the US FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted the risk-benefit balance supported it.

Sarepta SRP-9001 AC vote
An FDA official announces the advisory committee vote. • Source: Screenshot of FDA broadcast

More from US FDA Performance Tracker

More from Regulatory Trackers